Dal 30 novembre 2023 al 02 dicembre 2023
Melanoma Bridge

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma. 

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.  

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival. 

Since then, improved understanding of the tumor microenvironment and tumor immuno-evasion strategies has resulted in different approaches to target and harness the immune response.  Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma. The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.  

This year latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling and focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies.  

Then, the “Great Debate” sessions, where counterpoint views from leading experts on specific and very actual controversial clinical issues will be presented and discussed from different points of view. 



Paolo A. Ascierto - Direttore Dipartimento Oncologia Medica Melanoma, Immunoterapia Oncologica e Terapie Innovative, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli 


Questo corso è accreditato per le seguenti professioni:


FARMACISTA Farmacista pubblico del SSN, Farmacista territoriale, Farmacista di altro settore



MEDICO CHIRURGO Allergologia e Immunologia Clinica, Anatomia Patologica, Chirurgia Generale, Chirurgia Plastica e Ricostruttiva, Cure Palliative, Dermatologia e Venereologia, Ematologia, Farmacologia e Tossicologia Clinica, Genetica Medica, Geriatria, Igiene, Epidemiologia e Sanità Pubblica, Laboratorio Di Genetica Medica, Medicina Generale, Medicina Interna, Medicina Nucleare, Oncologia, Patologia Clinica, Radioterapia, Radiodiagnostica


Dal 30 novembre 2023 al 02 dicembre 2023

Napoli (NA), Napoli

Responsabile scientifico
Paolo A. Ascierto

Crediti attribuiti all'evento: 4,2

ID ECM: 327 -396007

Medico chirurgo, Farmacista, Biologo, Infermiere, Infermiere pediatrico

Evento accreditato per: 201

3P Solution s.r.l. a socio unico
Sede Legale: via Borgogna, 2 - 20122 Milano
Sede Operativa: Corso Europa, 13 - 20122 Milano
T: +39 02 36631574 - PEC
P.IVA/C.F. 06860060968 - REA MI-1919426 -
Soggetto a direzione e coordinamento di
Cencora Italy Holdings S.r.l, Milano -

Privacy Policy
Fatturazione Elettronica